STEVENAGE, England, September 27, 2017 /PRNewswire/ --
Extensive development & commercial expertise to guide company growth
NeRRe Therapeutics, which is developing a unique portfolio of neurokinin (NK)-1 receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity, has appointed Andrew Kay as Chairman of the Board. Mr. Kay, who has extensive product development and commercial experience across the pharma and biotechnology sectors, takes over from Dr Kaasim Mahmood of Advent, who remains on the Board. Following the demerger of KaNDy Therapeutics, announced today, NeRRe Therapeutics is primarily focused on its lead product orvepitant, which is in a multinational Phase IIb trial for chronic refractory cough.
Mr Kay has worked in the biotechnology sector as CEO of Algeta ASA, which was sold to Bayer for $2.9bn in 2014, and as Chief Commercial Officer and a Board Director of Renovo. He started his industry career in the pharmaceutical sector, working in international roles at Novartis, AstraZeneca and Eli Lilly, following a BPharm Hons degree from Nottingham University School of Pharmacy. Other current roles include Chairman of Blueberry Therapeutics, Chairman of Wilson Therapeutics and Senior Advisor to HealthCap VC. Mr Kay has also been appointed an adviser to KaNDy Therapeutics.
Dr Mary Kerr, CEO of NeRRe Therapeutics, said, "With his broad experience, Andrew's appointment as Chairman will bring tremendous value to the company as we advance orvepitant towards late-stage clinical development and commercialisation. NeRRe Therapeutics would also like to thank Kaasim for his guidance and we are pleased that he remains on the Board as Advent's representative."
Andrew Kay, Chairman of NeRRe Therapeutics, said, "With its focus on conditions caused by neuronal hypersensitivity related to neurokinin-1 receptor system dysfunction, the company has the opportunity to make a real difference in areas of unmet medical need such as chronic refractory cough. These are debilitating conditions for thousands of patients worldwide, and I am looking forward to helping NeRRe Therapeutics develop further."
A photograph of Andrew Kay is available on request
Notes to Editors
About NeRRe Therapeutics (http://www.nerretherapeutics.com)
NeRRe Therapeutics is a private UK based clinical-stage company developing a unique pipeline of three neurokinin (NK)-1 antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity associated with neurokinin-1 receptor system dysfunction. Its portfolio is tackling a range of disorders with high unmet need including chronic refractory cough and chronic pruritus. The company is led by an experienced management team including Dr Mary Kerr (CEO), formerly SVP and Global Franchise lead at GSK and Dr Mike Trower (Co-founder, CSO/COO), formerly VP & Head of the External Drug Discovery Group in the Neurosciences CEDD at GSK.
NeRRe Therapeutics was founded in 2012 as a spin out from GSK. Since it was founded, it has raised £31.5 million and is backed by leading international life sciences investors: Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners, OrbiMed, Novo A/S, and by GSK. KaNDy Therapeutics was spun out of NeRRe Therapeutics in September 2017. NeRRe Therapeutics is based at Stevenage Bioscience Catalyst. You can find more information about NeRRe Therapeutics at http://www.nerretherapeutics.com.
For more information, please contact:
Mary Kerr, CEO of NeRRe Therapeutics
SOURCE NeRRe Therapeutics